MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

Home・Elenco Azioni・Cogent Biosciences Inc

Cogent Biosciences Inc

Chiusa

35.65 0.88

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

34.21

Massimo

35.65

Metriche Chiave
By Trading Economics
Entrata	-22M -102M
Dipendenti	258
EBITDA	-30M -109M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+48.36% upside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	141M 5.7B
Apertura precedente	34.77
Chiusura precedente	35.65

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

4.88 / 5.87 Supporto e resistenza

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 apr 2026, 17:26 UTC

Principali Notizie su Eventi

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7 apr 2026, 23:55 UTC

Discorsi di Mercato

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7 apr 2026, 23:47 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Market Talk Roundup: Latest on U.S. Politics

7 apr 2026, 23:47 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7 apr 2026, 23:44 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7 apr 2026, 23:42 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

7 apr 2026, 23:42 UTC

Discorsi di Mercato

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7 apr 2026, 23:37 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7 apr 2026, 23:15 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7 apr 2026, 23:04 UTC

Principali Notizie su Eventi

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7 apr 2026, 23:04 UTC

Principali Notizie su Eventi

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7 apr 2026, 23:03 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 apr 2026, 23:03 UTC

Discorsi di Mercato

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7 apr 2026, 23:01 UTC

Principali Notizie su Eventi

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7 apr 2026, 22:58 UTC

Principali Notizie su Eventi

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7 apr 2026, 21:56 UTC

Acquisizioni, Fusioni, Takeovers

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7 apr 2026, 20:50 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Basic Materials Roundup: Market Talk

7 apr 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

7 apr 2026, 19:45 UTC

Discorsi di Mercato

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7 apr 2026, 19:17 UTC

Principali Notizie su Eventi

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7 apr 2026, 19:16 UTC

Discorsi di Mercato

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7 apr 2026, 19:07 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

7 apr 2026, 19:07 UTC

Discorsi di Mercato

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7 apr 2026, 18:41 UTC

Acquisizioni, Fusioni, Takeovers

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7 apr 2026, 18:40 UTC

Acquisizioni, Fusioni, Takeovers

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7 apr 2026, 18:39 UTC

Acquisizioni, Fusioni, Takeovers

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7 apr 2026, 18:24 UTC

Principali Notizie su Eventi

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7 apr 2026, 17:08 UTC

Discorsi di Mercato

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7 apr 2026, 16:21 UTC

Principali Notizie su Eventi

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7 apr 2026, 16:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

48.36% in crescita

Previsioni per 12 mesi

Media 52.55 USD 48.36%

Alto 64 USD

Basso 35 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.